Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- LG ElectronicsLG TO SUPPLY INTEGRATED COCKPIT SOLUTION FOR RENAULT GROUP'S FIRST COMMERCIAL SDVCompanies: LG ElectronicsRenaultConsolidation of Instrument Cluster and Infotainment System Helps Deliver a Unified In-Vehicle Experience and Optimized System Architecture News...
- LG ElectronicsLG TO SUPPLY INTEGRATED COCKPIT SOLUTION FOR RENAULT GROUP'S FIRST COMMERCIAL SDVCompanies: LG ElectronicsRenaultConsolidation of Instrument Cluster and Infotainment System Helps Deliver a Unified In-Vehicle Experience and Optimized System Architecture News Summary LG Electronics will supply its integrated cockpit solution for Renault Group's New Trafic E-Tech Electric, the automaker's first...
- Applied Intuition annonce un partenariat avec Nissan pour fournir une plateforme de développement native pour l'IA et soutenir le développement de véhicules définis par l'IACompanies: NissanApplied Intuition fournira son logiciel Vehicle OS et soutiendra le développement des SDV (véhicules définis par logiciel) de nouvelle génération de Nissan grâce à ses outils de développement natifs pour l'IA, prolongeant ainsi une collaboration qui a débuté en 2020. SUNNYVALE,...
- Omega HoldingsWells Vehicle Electronics Announces New President, Joe RobinsonWells Vehicle Electronics, a leading global source of advanced vehicle electronics solutions and a member of the Omega Holdings family of companies, today announced the appointment of Joe Robinson as President, effective October 15, 2026....
- Trinity Industries, Inc.Trinity Industries Statement on Antidumping and Countervailing Duty Petition Filed Against Railway Tank Car Imports from MexicoDALLAS, October 05, 2026--Trinity Industries, Inc. (NYSE: TRN) ("Trinity"), a leading provider of railcar products and services across North America, is aware of and will fully defend against the antidumping and countervailing duty petition filed by UTLX Manufacturing LLC ("UTLX"), a wholly owned subsidiary of Berkshire Hathaway, Inc. UTLX filed its petition with the U.S.
- Lattis Management LPLattis Management LP Completes Second Close of its Flagship VehicleNEW YORK & LONDON & AUSTIN, October 05, 2026--Lattis Management LP ("Lattis"), a provider of infrastructure and commodities solutions for middle-market energy, completed a second capital close for its flagship vehicle Lattis LP and the inauguration of its infrastructure-focused vehicle, Lattis Infrastructure LP. Lattis received investor commitments exceeding $100 million early in the third quarter, anchored by a Northeastern institutional investor with over $25 billion in assets. Several notable
- Anixa Biosciences, Inc.Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical TrialFirst patient in current dose cohort exhibited no progression of her cancer three months after treatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 -- Anixa...
- Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon CanadaNAPERVILLE, IL, Oct 5, 2026 - Neil Harrison joins Chervon as Vice President Sales, Marketing and Managing Director for Chervon Canada; effective Monday, October 5, 2026, reporting to CEO Joe Galli. Harrison brings more than 23 years of professional and consumer power tools experience. After studying environmental research management and graduating of the University of Western Ontario in London, Ontario; Harrison began his tool career in 2003 with Black & Decker/DeWalt, advancing through various positions in sales, operations, and product management. In 2006, Harrison joined Bosch Canada as marketing manager for the SKIL brand. He then went on to a position as an account manager with Hilti Canada. In 2008, Harrison joined TTI/Milwaukee, where he launched an impressive 17-year career advancing through leadership positions in product management, channel management, and marketing management. He went on to lead regional sales teams in the industrial construction channels for Ontario and eastern Canada and also built and managed a national field sales team for the hardware and automotive channels. Most recently, Harrison was the managing director for Klingspor Abrasives Canada where he oversaw the entire Canadian business including sales, marketing, warehouse and operations, human resources, and finance. Throughout his career, Harrison has distinguished himself as a strong leader with a track record for developing exceptional people, brands, customer relationships and growing business units in the Canadian theater. "We are delighted to now have Neil in place as our leader of Chervon Canada, says CEO Joe Galli. Neil's impressive leadership skills, business management skills and customer-centricity make him an ideal candidate to lead our Canadian business." "I can't wait to get started in building and leading our Canadian business unit here at Chervon," said Harrison. "Chervon is clearly making a commitment to developing a leadership Canadian business, and I am enormously grateful to lead this new effort." About Chervon Chervon North America is part of a global total solution provider specializing in R&D, manufacturing, testing, sales, and after-sales service of power tools and outdoor power equipment (OPE). Guided by user-centric innovation, the Company operates an integrated business model supported by global sales and distribution networks. Chervon's portfolio includes EGO, FLEX, SKIL, and DEVON, serving industrial, professional, and consumer markets globally. Better Tools. Better World. Chervon is committed to delivering superior products to users worldwide through continuous innovation and strives to become a global leader in power tools and OPE in the lithium-ion, intelligent, and digital era. PR Contact: Corporate Communications [email protected] SOURCE: Chervon
- Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal DiseaseHong Kong, Oct 5, 2026 - At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), one of the world’s most influential scientific meetings in diabetes and metabolic disease, Micot Pharmaceuticals (02335.HK) presented research on XTL6001, its internally developed long-acting protein candidate and triple receptor agonist targeting GLP-1R, GCGR and MasR. The studies, covering high-quality weight management and chronic kidney disease (CKD)/diabetic kidney disease (DKD), were selected for oral presentation, bringing the Chinese-origin innovative programme onto a leading international scientific platform. From a development perspective, XTL6001 is not designed simply to maximise headline weight loss. By combining the GLP-1R, GCGR and MasR pathways, the programme aims to address weight management, glucose and lipid metabolism, body-composition optimisation and potential renal protection within a single development framework. As the GLP-1 field continues to evolve rapidly, this integrated metabolic–renal approach gives XTL6001 a differentiated profile versus conventional incretin-based therapies and provides a clearer positioning for subsequent global clinical development and potential business development opportunities. From Posters to Oral Presentations: Building International Scientific Visibility EASD and the American Diabetes Association (ADA) Scientific Sessions are among the most prominent international scientific platforms in diabetes and metabolic disease. Research on XTL6001 was first presented in two posters at ADA 2026 in June, followed by two oral presentations at EASD. The progression from posters to oral presentation provided a higher-profile forum for the same development thesis to be presented and discussed with the international scientific community. Conference selection, of course, does not substitute for clinical validation. For an early-stage innovative programme, however, repeated exposure at major international meetings can help increase visibility among clinicians, research institutions and potential industry partners. Notably, XTL6001 presented both weight-management and CKD/DKD research at the same EASD meeting. Obesity care is increasingly moving beyond “weight loss alone” toward broader management of body composition and cardiometabolic, hepatic and renal comorbidities. The ability to deliver benefits beyond weight reduction is therefore becoming an important dimension of next-generation competition. By adding MasR to the GLP-1R/GCGR combination, XTL6001 is designed to incorporate a renal-protection component into its differentiated product profile. Weight Loss, Muscle Preservation and Renal Protection: Differentiation Through a Triple-Target Mechanism According to company disclosures and publicly available scientific data, XTL6001 is a long-acting protein drug candidate and a triple receptor agonist targeting GLP-1R, GCGR and MasR. The programme has completed its Phase I study in China and has received clinical trial authorisation in both China and the United States. In the disclosed Phase I single ascending dose (SAD) study, 25 healthy participants received XTL6001 across a dose range of 37.5–300 mg, with additional participants receiving placebo. The study showed a favourable overall safety and tolerability profile. Dr. Xiangling Wang, Micot Pharma’s Chief Medical Officer (CMO), presented a systematic study comparing XTL6001 The available data also indicate that XTL6001 is designed to deliver benefits beyond the headline weight loss shown on the scale. In preclinical diet-induced obesity (DIO) mouse studies, XTL6001 demonstrated greater weight reduction than semaglutide at equivalent doses and a slower rate of weight regain after treatment discontinuation. At the same dose, and despite overall food intake being comparable to or even higher than that observed with semaglutide, weight reduction was approximately 33% greater, suggesting that the effect may be driven more by increased energy expenditure and fat utilisation than by appetite suppression alone. The studies also showed selective fat loss, restoration of the proportion of muscle mass toward normal levels, a 1.61-fold greater reduction in abdominal fat versus semaglutide, and concurrent improvements in lipid and hepatic parameters, including a reduction in LDL-C of more than 80% (87.2%) and a 90.8% reduction in hepatic triglycerides, with near-complete reversal of hepatic steatosis and normalisation of ALT. These findings point to potential utility in MASH. Importantly, the comparisons with semaglutide were generated primarily in animal studies and should not be interpreted as evidence of superior efficacy in humans. In the renal programme, publicly disclosed studies used multiple animal models of kidney disease. The rationale for the triple-target mechanism can be summarised as follows: GLP-1R primarily supports improvements in metabolism and haemodynamics; GCGR may help protect renal tubules from lipotoxic injury; and MasR is intended to address glomerular structural protection and antifibrotic activity. Together, the three pathways are designed to intervene across metabolic drivers, haemodynamic abnormalities, structural injury and fibrosis in the CKD/DKD disease cascade, rather than acting as a simple combination of independent effects. XTL6001 dose-dependently reduced 24-hour urinary albumin excretion and the urine albumin-to-creatinine ratio (UACR), while improving the glomerular filtration rate (GFR). Across different models, XTL6001 showed dose-dependent reductions in albuminuria: in STZ-induced, uninephrectomised rats, 0.5 mg/kg reduced UACR by 62.9% versus vehicle control and reduced 24-hour urinary albumin by approximately 54.7%; in the alloxan model, the reduction in UACR was approximately three times that seen with finerenone monotherapy; and in a mouse CKD model, 12 mg/kg reduced urinary albumin by 80.2%, with reductions in albuminuria reaching approximately 88% across the three models. The studies also observed reductions in serum creatinine, blood urea nitrogen and serum uric acid. These findings provide further support for the programme’s “weight management–metabolic regulation–albuminuria reduction” rationale. However, the renal benefits remain predominantly preclinical and will need to be validated in randomised controlled studies in patients with CKD/DKD. The Obesity Market Is Moving Into a Multi-Target Era — MasR Gives XTL6001 a Distinct Route The next generation of obesity therapies is already progressing from single-target GLP-1 agents toward GLP-1/GIP dual agonists, GLP-1/GCGR dual agonists and GLP-1/GIP/GCGR triple agonists. Eli Lilly’s retatrutide has advanced into Phase III development, while United Laboratories’ UBT251 is in Phase II, underscoring that “multi-target” activity alone is no longer sufficient to create a durable moat. XTL6001 is differentiated by the fact that its third target is MasR rather than GIPR. According to company disclosures, activation of the MasR pathway is associated with anti-inflammatory and antifibrotic effects, promotion of muscle-protein synthesis, improvement in mitochondrial function and induction of mitochondria-mediated thermogenesis. This gives XTL6001 a development rationale that is more naturally centred on renal protection, proteinuria and broader multi-organ metabolic benefits, rather than on cross-trial comparisons of headline weight-loss efficacy where no head-to-head evidence exists. From a capital-markets and business-development perspective, XTL6001’s successive appearances at ADA and EASD, together with its upcoming presentation of hyperuricaemic nephropathy research at ASN Kidney Week 2026, are helping the programme build continuous visibility across the diabetes, obesity and nephrology communities. Presenting at international scientific meetings is not a transaction in itself, nor can it replace human efficacy data, but it can create additional touchpoints with potential licensing, co-development and regional partners. Ultimately, the asset’s value will depend on whether clinical studies in humans can validate the hypotheses around quality of weight loss, body-composition improvement and renal protection; whether its safety and tolerability profile remains competitive; and whether indications such as CKD/DKD can demonstrate reproducible and clinically translatable benefits. If these elements are progressively validated, XTL6001 could establish a more distinctive global development path in the increasingly crowded GLP-1 landscape through a combined positioning around high-quality weight management, metabolic improvement and potential renal protection.
- Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal DiseaseHong Kong, Oct 5, 2026 - At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), one of the world’s most influential scientific meetings in diabetes and metabolic disease, Micot Pharmaceuticals (02335.HK) presented research on XTL6001, its internally developed long-acting protein candidate and triple receptor agonist targeting GLP-1R, GCGR and MasR. The studies, covering high-quality weight management and chronic kidney disease (CKD)/diabetic kidney disease (DKD), were selected for oral presentation, bringing the Chinese-origin innovative programme onto a leading international scientific platform. From a development perspective, XTL6001 is not designed simply to maximise headline weight loss. By combining the GLP-1R, GCGR and MasR pathways, the programme aims to address weight management, glucose and lipid metabolism, body-composition optimisation and potential renal protection within a single development framework. As the GLP-1 field continues to evolve rapidly, this integrated metabolic–renal approach gives XTL6001 a differentiated profile versus conventional incretin-based therapies and provides a clearer positioning for subsequent global clinical development and potential business development opportunities. From Posters to Oral Presentations: Building International Scientific Visibility EASD and the American Diabetes Association (ADA) Scientific Sessions are among the most prominent international scientific platforms in diabetes and metabolic disease. Research on XTL6001 was first presented in two posters at ADA 2026 in June, followed by two oral presentations at EASD. The progression from posters to oral presentation provided a higher-profile forum for the same development thesis to be presented and discussed with the international scientific community. Conference selection, of course, does not substitute for clinical validation. For an early-stage innovative programme, however, repeated exposure at major international meetings can help increase visibility among clinicians, research institutions and potential industry partners. Notably, XTL6001 presented both weight-management and CKD/DKD research at the same EASD meeting. Obesity care is increasingly moving beyond “weight loss alone” toward broader management of body composition and cardiometabolic, hepatic and renal comorbidities. The ability to deliver benefits beyond weight reduction is therefore becoming an important dimension of next-generation competition. By adding MasR to the GLP-1R/GCGR combination, XTL6001 is designed to incorporate a renal-protection component into its differentiated product profile. Weight Loss, Muscle Preservation and Renal Protection: Differentiation Through a Triple-Target Mechanism According to company disclosures and publicly available scientific data, XTL6001 is a long-acting protein drug candidate and a triple receptor agonist targeting GLP-1R, GCGR and MasR. The programme has completed its Phase I study in China and has received clinical trial authorisation in both China and the United States. In the disclosed Phase I single ascending dose (SAD) study, 25 healthy participants received XTL6001 across a dose range of 37.5–300 mg, with additional participants receiving placebo. The study showed a favourable overall safety and tolerability profile. Dr. Xiangling Wang, Micot Pharma’s Chief Medical Officer (CMO), presented a systematic study comparing XTL6001 The available data also indicate that XTL6001 is designed to deliver benefits beyond the headline weight loss shown on the scale. In preclinical diet-induced obesity (DIO) mouse studies, XTL6001 demonstrated greater weight reduction than semaglutide at equivalent doses and a slower rate of weight regain after treatment discontinuation. At the same dose, and despite overall food intake being comparable to or even higher than that observed with semaglutide, weight reduction was approximately 33% greater, suggesting that the effect may be driven more by increased energy expenditure and fat utilisation than by appetite suppression alone. The studies also showed selective fat loss, restoration of the proportion of muscle mass toward normal levels, a 1.61-fold greater reduction in abdominal fat versus semaglutide, and concurrent improvements in lipid and hepatic parameters, including a reduction in LDL-C of more than 80% (87.2%) and a 90.8% reduction in hepatic triglycerides, with near-complete reversal of hepatic steatosis and normalisation of ALT. These findings point to potential utility in MASH. Importantly, the comparisons with semaglutide were generated primarily in animal studies and should not be interpreted as evidence of superior efficacy in humans. In the renal programme, publicly disclosed studies used multiple animal models of kidney disease. The rationale for the triple-target mechanism can be summarised as follows: GLP-1R primarily supports improvements in metabolism and haemodynamics; GCGR may help protect renal tubules from lipotoxic injury; and MasR is intended to address glomerular structural protection and antifibrotic activity. Together, the three pathways are designed to intervene across metabolic drivers, haemodynamic abnormalities, structural injury and fibrosis in the CKD/DKD disease cascade, rather than acting as a simple combination of independent effects. XTL6001 dose-dependently reduced 24-hour urinary albumin excretion and the urine albumin-to-creatinine ratio (UACR), while improving the glomerular filtration rate (GFR). Across different models, XTL6001 showed dose-dependent reductions in albuminuria: in STZ-induced, uninephrectomised rats, 0.5 mg/kg reduced UACR by 62.9% versus vehicle control and reduced 24-hour urinary albumin by approximately 54.7%; in the alloxan model, the reduction in UACR was approximately three times that seen with finerenone monotherapy; and in a mouse CKD model, 12 mg/kg reduced urinary albumin by 80.2%, with reductions in albuminuria reaching approximately 88% across the three models. The studies also observed reductions in serum creatinine, blood urea nitrogen and serum uric acid. These findings provide further support for the programme’s “weight management–metabolic regulation–albuminuria reduction” rationale. However, the renal benefits remain predominantly preclinical and will need to be validated in randomised controlled studies in patients with CKD/DKD. The Obesity Market Is Moving Into a Multi-Target Era — MasR Gives XTL6001 a Distinct Route The next generation of obesity therapies is already progressing from single-target GLP-1 agents toward GLP-1/GIP dual agonists, GLP-1/GCGR dual agonists and GLP-1/GIP/GCGR triple agonists. Eli Lilly’s retatrutide has advanced into Phase III development, while United Laboratories’ UBT251 is in Phase II, underscoring that “multi-target” activity alone is no longer sufficient to create a durable moat. XTL6001 is differentiated by the fact that its third target is MasR rather than GIPR. According to company disclosures, activation of the MasR pathway is associated with anti-inflammatory and antifibrotic effects, promotion of muscle-protein synthesis, improvement in mitochondrial function and induction of mitochondria-mediated thermogenesis. This gives XTL6001 a development rationale that is more naturally centred on renal protection, proteinuria and broader multi-organ metabolic benefits, rather than on cross-trial comparisons of headline weight-loss efficacy where no head-to-head evidence exists. From a capital-markets and business-development perspective, XTL6001’s successive appearances at ADA and EASD, together with its upcoming presentation of hyperuricaemic nephropathy research at ASN Kidney Week 2026, are helping the programme build continuous visibility across the diabetes, obesity and nephrology communities. Presenting at international scientific meetings is not a transaction in itself, nor can it replace human efficacy data, but it can create additional touchpoints with potential licensing, co-development and regional partners. Ultimately, the asset’s value will depend on whether clinical studies in humans can validate the hypotheses around quality of weight loss, body-composition improvement and renal protection; whether its safety and tolerability profile remains competitive; and whether indications such as CKD/DKD can demonstrate reproducible and clinically translatable benefits. If these elements are progressively validated, XTL6001 could establish a more distinctive global development path in the increasingly crowded GLP-1 landscape through a combined positioning around high-quality weight management, metabolic improvement and potential renal protection.
- Cheche Group Looks to Australia as Home Batteries Take on a Bigger Grid RoleHONG KONG, Oct 5, 2026 - Australia’s rapidly expanding home battery market is becoming more than a story about hardware sales, as government subsidies accelerate adoption and virtual power plant programs draw household batteries into the wider electricity system. The shift provides the backdrop to Cheche Group Inc.’s (Nasdaq: CCG) proposed move into residential energy storage. Cheche said earlier this month that it had signed a non-binding term sheet for a strategic investment in Long Way Fortune, a residential solar-and-storage business operating in Australia and Singapore. The transaction remains subject to due diligence, definitive agreements and relevant approvals. The proposal would take Cheche beyond its core digital insurance and mobility businesses at a time when Australia is committing significant public funding to the residential energy storage sector. Since July 2025, the federal Cheaper Home Batteries Program has provided an upfront discount of around 30% for a range of eligible battery systems, with support now tiered by system size and set to decline over time. The government later expanded estimated four-year funding to A$7.2 billion, a move expected to help more than 2 million Australians install a battery and add roughly 40 gigawatt-hours of storage capacity by 2030. As installations rise, attention is also shifting to how those batteries are used once they are in homes. In Western Australia, households receiving state battery rebates or no-interest loans are required to participate in a virtual power plant, or VPP, while New South Wales has taken a different approach by offering incentives for eligible battery owners to connect their systems to one. VPPs allow household batteries to be coordinated in response to electricity prices, periods of peak demand and broader grid conditions. For homeowners, a battery can still lower electricity bills or provide backup power, but once connected to a VPP it can also form part of a larger pool of distributed energy capacity. That is gradually broadening the economics of residential storage. Much of the industry has traditionally revolved around selling and installing equipment, but a growing base of connected batteries is creating opportunities around aggregation, electricity management and services linked to how those assets are operated over time. Hardware performance, pricing and installation will remain central to adoption. In markets where batteries are increasingly connected with electricity retailers, VPPs and grid programs, however, the commercial relationship can extend well beyond the initial equipment sale. Cheche has placed the proposed investment within its broader “Green Mobility + Green Energy” strategy. While Cheche’s existing digital insurance business and Long Way Fortune’s energy storage solutions currently operate independently, both teams are actively exploring cross-sector synergies within the EV and green energy supply chains. Detailing of operational integration is expected as negotiations progress. The near-term relevance of the proposal therefore lies less in any immediate overlap with Cheche’s existing business than in exposure to a part of the energy market undergoing rapid change. Australia is adding household batteries at scale while also developing ways for those assets to participate more actively in the electricity system. As more systems are connected, residential storage is beginning to move beyond a largely product-driven market. Energy storage equipment sales remain important, but aggregation and ongoing energy services could account for a larger share of the value created around those systems over time. Unlocking the full value of this transition will depend on finalizing the transaction and executing its operational integration. Australia’s battery subsidies are putting more storage into homes, while VPP programs are beginning to shape how those batteries interact with the electricity market once installed. For companies entering the sector, the opportunity is increasingly tied not only to rising demand for batteries, but also to the changing role those assets play after they are connected.
- The General InsuranceThe General Insurance® Gives Street Fighter's Iconic Beat-Up Car a BreakFans have a chance to win a real-life, fully pixelated recreation of the Street Fighter II Bonus Stage Car that Street Fighter players have spent decades smashing in the game's infamous Bonus Stage — The General Insurance® believes everyone...